CGX-635-CML-201: Phase II open-label study to evaluate the efficacy and safety of intravenous administration of omacetaxine combined with the oral administration of imatinib mesylate (Gleevec®) in the treatment of patients with chronic myeloid leukemia (CML) in chronic, accelerated and blast phase.

CGX-635-CML-202: A multi-center phase II open-label study to evaluate the efficacy and safety of subcutaneous administration of omacetaxine in the treatment of patients with chronic myeloid leukemia (CML) in chronic, accelerated and blast phase who have tested positive for the T315I bcr-abl point mutation.